© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 17, 1453-1458,
September 1, 1999
© 1999 Oxford University Press
COMMENTARY |
Perspective on Kaposi's Sarcoma: Facts, Concepts, and Conjectures
Affiliations of authors: M. S. Reitz, Jr., R. C. Gallo, Institute of Human Virology, University of Maryland at Baltimore; L. S. Nerurkar, International Cancer Information Center, National Cancer Institute, Bethesda, MD.
Correspondence to: Robert C. Gallo, M.D., Institute of Human Virology, University of Maryland at Baltimore, 725 W. Lombard St., Rm. S307, Baltimore, MD 21201-1192 (e-mail: coleman@umbi.umd.edu).
| INTRODUCTION |
|---|
Kaposi's sarcoma (KS) is the most common tumor associated with human immunodeficiency virus type 1 (HIV-1) infection, occurring in approximately 30% of HIV-1-infected homosexual men. The incidence of KS has increased in this risk group by more than 100 000-fold relative to the general population (1,2). However, KS is also increased in nonhomosexual HIV-infected males by about 10 000-fold (2,3). In the absence of HIV-1 infection, KS occurs very rarely in three distinct epidemiologic forms: 1) the classic form (disease seen in older men from certain ethnic groups) (4,5), 2) the endemic form (prevalent in some parts of equatorial Africa) (5,6), and 3) a form associated with renal transplant patients (7,8). It has not been clear whether all four forms of KS represent the same disease, or, like leukemias, lymphomas,
| KS Cell Types |
|---|
| Production of Growth Factors by KS Cells |
|---|
| Role of HIV-1 Tat |
|---|
| Presence of Tat in KS Cells |
|---|
| Role of HIV-1 |
|---|
| KS and Malignancy |
|---|
| Human Herpesvirus 8 |
|---|
| NOTES |
|---|
| REFERENCES |
|---|
This article has been cited by other articles:
![]() |
A. Y. Khakoo, S. Pati, S. A. Anderson, W. Reid, M. F. Elshal, I. I. Rovira, A. T. Nguyen, D. Malide, C. A. Combs, G. Hall, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma J. Exp. Med., May 15, 2006; 203(5): 1235 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Lee, S.-H. Lee, P. Feng, H. Chang, N.-H. Cho, and J. U. Jung Characterization of the Kaposi's Sarcoma-Associated Herpesvirus K1 Signalosome J. Virol., October 1, 2005; 79(19): 12173 - 12184. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Lee, M. Connole, Z. Tang, N. L. Harris, and J. U. Jung Structural Analysis of the Kaposi's Sarcoma-Associated Herpesvirus K1 Protein J. Virol., July 15, 2003; 77(14): 8072 - 8086. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pati, J. S. Foulke Jr., O. Barabitskaya, J. Kim, B. C. Nair, D. Hone, J. Smart, R. A. Feldman, and M. Reitz Human Herpesvirus 8-Encoded vGPCR Activates Nuclear Factor of Activated T Cells and Collaborates with Human Immunodeficiency Virus Type 1 Tat J. Virol., May 15, 2003; 77(10): 5759 - 5773. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hwang, D. Lee, Y. Gwack, H. Min, and J. Choe Kaposi's sarcoma-associated herpesvirus K8 protein interacts with hSNF5 J. Gen. Virol., March 1, 2003; 84(3): 665 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pati, C. B. Pelser, J. Dufraine, J. L. Bryant, M. S. Reitz Jr, and F. F. Weichold Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma Blood, May 15, 2002; 99(10): 3771 - 3779. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chung, R. E. Means, J.-K. Choi, B.-S. Lee, and J. U. Jung Kaposi's Sarcoma-Associated Herpesvirus OX2 Glycoprotein Activates Myeloid-Lineage Cells To Induce Inflammatory Cytokine Production J. Virol., April 16, 2002; 76(10): 4688 - 4698. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. X. Zhu, S. M. King, E. J. Smith, D. E. Levy, and Y. Yuan A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation PNAS, April 8, 2002; (2002) 82420599. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zim, D. Maceri, D. H. Rice, and A. Fedenko Quiz Case 1 Arch Otolaryngol Head Neck Surg, November 1, 2000; 126(11): 1390 - 1393. [Full Text] [PDF] |
||||
![]() |
R. Weiss and C. Boshoff Addressing Controversies Over Kaposi's Sarcoma J Natl Cancer Inst, May 3, 2000; 92(9): 677 - 679. [Full Text] [PDF] |
||||
![]() |
J.-G. Judde, V. Lacoste, J. Briere, E. Kassa-Kelembho, E. Clyti, P. Couppie, C. Buchrieser, M. Tulliez, J. Morvan, and A. Gessain Monoclonality or Oligoclonality of Human Herpesvirus 8 Terminal Repeat Sequences in Kaposi's Sarcoma and Other Diseases J Natl Cancer Inst, May 3, 2000; 92(9): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. X. Zhu, S. M. King, E. J. Smith, D. E. Levy, and Y. Yuan A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation PNAS, April 16, 2002; 99(8): 5573 - 5578. [Abstract] [Full Text] [PDF] |
||||






